They are used in treating serious conditions such as cancer, autoimmune disorders and diabetes, where biologic therapies are essential but often prohibitively expensive. Typically priced 15 – 35% lower than reference biologics, biosimilars expand access to treatment for patients who might otherwise go without care [1]. Global revenues in the biosimilars market are projected to grow from $40 billion in 2025 to $176 billion by 2034, driven by loss of exclusivity for many biologics and rising prevalence of chronic diseases [2]. In the US alone, 118 biologics are expected to lose patent protection between 2025 and 2034, yet only 10% currently have biosimilars in development [3]. Primary barrier – complex approval processes and extensive data requirements.

 

 

The regulatory challenge

Demonstrating biosimilarity requires comprehensive comparability studies. Unlike small-molecule generics, which can be exactly replicated, biosimilars exhibit inherent variability that requires constant analytical monitoring throughout the product lifecycle. Because biosimilars are produced in living systems, even minor manufacturing changes can affect immunogenicity or quality [4]. Regulators evaluate biosimilarity based on the “totality of the evidence” meaning a combined review of analytical, non-clinical and clinical data [5,6]. This approach includes review of structural characterization, functional assays, animal data, pharmacokinetic (PK) and pharmacodynamic (PD) data, immunogenicity data, and comparative clinical studies. All of these generate large heterogeneous evidence packages. Regulators require these datasets to be integrated into clear, comparable safety profile across pre- and post‑authorization documents. Success depends on accurate and consistent regulatory documentation at every stage: development, submission, and post-authorization surveillance.

 

Core safety documents we prepare

PrimeVigilance specializes in preparing core safety documents required across the entire lifecycle of a biosimilar and aligns them with ICH, EMA and FDA requirements:

Development Safety Update Reports (DSURs): Biosimilar programs often have fewer patients and narrower trials (Phase I and III studies). Typically, safety concerns are inherited from the reference product (“lean” approach). DSURs summarize PK/PD, immunogenicity and clinical trial findings placing those results in the context of the reference product’s established safety profile. DSURs must flag emerging signals for downstream inclusion in the Risk Management Plan (RMP) and future Aggregate Reports.

Risk Management Plans: RMPs for biosimilars are lifecycle documents that are based on the knowledge and experience from the reference product but focused on biosimilar-specific risks, such as immunogenicity and traceability. Over time, the RMP is expected to evolve as new knowledge emerges. Safety findings identified in a DSUR must flow into the RMP and be reflected in subsequent Periodic Benefit-Risk Evaluation Reports (PBRERs), Periodic Safety Update Reports (PSURs) or Periodic Adverse Experiences Reports (PAERs) with consistent presentation and benefit-risk interpretation.

Post-authorization documents (PBRERs, PSURs and PAERs): Clinical development programs for biosimilars often enroll fewer patients than originator trials, thus rare adverse events may only appear after broad post-marketing exposure. These documents incorporate large numbers of spontaneous and literature reports. We leverage advanced safety databases and literature search strategies to handle high volumes of reports while differentiating biosimilar signals from those of the reference product.

In addition to these reports PrimeVigilance also supports ad hoc regulatory requests that may arise during the assessment process (e.g., requests for supplementary analyses or RMP amendments). For complex or jurisdiction-specific issues, we coordinate with regulatory intelligence, strategic advisors, and QPPVs to ensure submissions reference the correct local requirements.

 

Preventing common setbacks – proactive approach

Regulators expect a single, traceable safety presentation that links DSURs, the RMP and Aggregate Reports. Fragmented presentation or unsupported statements erode the integrity of safety surveillance, invite queries, and delay approvals. Discrepancies can imply inadequate monitoring or poor internal communication. PrimeVigilance mitigates these through clean workflows and robust standard operating procedures. We map deliverables to regulatory deadlines, allocate resources to each milestone, and use harmonized templates and standardized tabulations so datasets, scopes and periodicities align across submissions. We build traceability, ensuring signals flagged in a DSUR are taken into account when preparing RMP and PBRER/PAER. All drafts go through rigorous review processes. The result is audit-ready and harmonized documentation that preserves scientific clarity, and maintains a single, reliable safety narrative from development through post-authorization.

 

Why partner with PrimeVigilance

Attempting to manage biosimilar documentation in-house can overwhelm development teams. Each report requires understanding of analytical, non-clinical and clinical data, as well as deep familiarity with evolving regulatory frameworks across different regions. Errors, inconsistencies, or delays in submissions can stall approvals and create costly setbacks.

By partnering with PrimeVigilance, Sponsors gain:

• Regulatory expertise: Deep knowledge of EMA, FDA, and ICH requirements.
• Experience: More than 1500 Aggregate Reports submitted per year.
• Accuracy and compliance: Rigorous QC processes and alignment with the latest guidance.
• Efficiency: Proven SOPs and templates that streamline preparation.
• Continuity: Harmonized documents for establishing safety profile from development to post-marketing.

For biosimilars, documentation is the foundation of regulatory approval and sustained market access. Professional medical writing ensures that complex scientific evidence is transformed into persuasive, compliant submissions. By partnering with PrimeVigilance, biosimilar developers can focus on innovation and market strategy, confident that their regulatory obligations are handled with precision and expertise.

 

 

References

1. Feng K, Russo M, Maini L, Kesselheim AS, Rome BN. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition. JAMA Health Forum. 2024 Mar 29;5(3):e235429.
2. Biosimilars Market Size to Hit USD 175.99 Billion by 2034
3. Assessing the Biosimilar Void in the U.S. – IQVIA
4. EMA. Biosimilars in the EU – Information guide for healthcare professionals; 2023.
5. FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry; 2015.
6. EMA. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1); 2014.